BioSpace News Archive

NRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage, biopharmaceutical company, today provided a new safety update on ZYESAMI.

Evelo Biosciences, Inc. today announced that the Company has been added to the NASDAQ Biotechnology Index ® (Nasdaq: NBI), effective prior to market open on December 20, 2021.

Ultra-large volume wearable injectors are devices that are able to store high volume of drugs and are designed to deliver the drug subcutaneously over an extended period of time.

The staphylococcal infection drugs market has been expected to grow significantly in the upcoming years. This market growth is on the back of the contagious nature of the infection.

Neonatal jaundice is the yellowish discoloration of the skin, conjunctiva, and the sclera due to elevated serum or plasma bilirubin in the newborn period.

Heparin-induced thrombocytopenia is one of the most common side effects of heparin therapy. A number of thrombotic conditions need heparin therapy to reduce the risk of thrombosis.

Fact.MR – A Market Research and Competitive Intelligence Provider: The global cosmetic dentistry market is expected to grow significantly during the projected period of 2021-2031.

Anastrozole is an oral non-selective aromatase inhibitor approved for adjuvant treatment of early-stage, hormone receptor-positive breast cancer in postmenopausal women.

Pixium Vision SA announces that it will attend the 11th Annual LifeSci Partners Corporate Access Event, being held virtually from January 5 to 7, 2022.

Cellworks Group, Inc., today announced results from the myCare-023 clinical trial, which found that the Cellworks Biosimulation Platform with its Therapy Response Index (TRI) reliably predicts complete response (CR) and overall survival (OS) for individual Acute Myeloid Leukemia (AML) patients beyond physician prescribed treatment.